Pegcetacoplan Delivers Real‐World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real‐World Clinical and Patient‐Reported Outcomes
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70228 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Juan Carlos Vallejo Llamas und 4 weiteren Autor:innen. Beteiligte Einrichtung: University Clinical Hospital of Salamanca, Salamanca, Spain. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired, non‐malignant haematological disorder that, if left untreated, can lead to significant morbidity. This systematic literature review (SLR) summarized real‐world evidence (RWE) for pegcetacoplan, a complement 3/3b inhibitor (C3i) available since 2021.
Methods
The SLR (PROSPERO‐CRD420251043506) followed 2020 PRISMA guidelines and included RW studies of pegcetacoplan ( n > 1 pts.; English; to April 2025) in adults (age ≥ 18 years) with PNH.
Results
Of 409 identified records, 39 qualified, representing 12 distinct studies. Six studies ( n = 4–39) reported median haemoglobin (Hb) with baseline 8.1–9.6 g/dL. Ending median Hb and maximum pegcetacoplan durations were: 12.0 g/dL at 12 months, 11.1–12.1 g/dL at 6 months (3 studies), and 11.1 g/dL at 3 months (1 study). In 4 other studies ( n = 48–70), ending mean Hb (maximum pegcetacoplan duration) was: 11.3 g/dL (7.2 months), 11.5 g/dL (6.6 months), 11.5 g/dL (5.9 months), and 11.58 g/dL (3 months). Six studies reported reduced absolute reticulocyte count (ARC; n = 4–39) from baseline median 155–301 × 10 9 /L to median 56–106 × 10 9 /L from 14 days of pegcetacoplan, maintained to maximum pegcetacoplan of 1–12 months. Three studies reported lactate dehydrogenase (LDH; n = 4–62); all showed reductions from baseline median 543.0 to 161.7 U/L after 3 months, and baseline median 299.5–316.0 U/L to 193.5–187.0 U/L after 6 months of pegcetacoplan. In complement 5 inhibitor‐naïve, LDH reduced from 977.8 to 358.9 U/L after 8.4 months, and 503.6 to 292.5 U/L in C5i‐experienced after 7.2 months. Three studies ( n = 4–63) reported reduced LDH from above the upper limit of normal levels. Six studies ( n = 23–70) reported reduced red blood cell transfusions (RBCt) after maximum pegcetacoplan durations of up to 12 months, and median durations of 3.0 and 10.2 months. Functional Assessment of Chronic Illness Therapy (FACIT)‐Fatigue scale scores in 1 study increased from baseline (mean 28.4) to 38.6 at 3 months, 36.3 at 6 months, and 34.9 at 9 months of pegcetacoplan treatment. Two studies reported FACIT‐Fatigue scores of 34.6–40.1 with pegcetacoplan for ≥ 1 month. EQ‐5D mean utility scores (0.85–0.94) in 2 studies were comparable to population normative values. On the Short‐Form 36 Health Survey, mental and physical component scores were slightly lower than US normative values.
Conclusions
RWE indicates pegcetacoplan is associated with improved haematological outcomes, reduced RBCt dependence and fatigue, and enhanced HRQoL. These findings from real‐world studies with diverse cohorts support generalizability and are broadly comparable with clinical trial evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Clinical Hospital of Salamanca, Salamanca, Spain.
- Sobi, Stockholm, Sweden.
- Oxford Pharmagenesis Ltd, Oxford, UK.
- Dipartimento di Scienze di Laboratorio Ed Ematologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
ORCID-Profile: Vikte Lionikaite
Zitieren
APA
Llamas, J. C. V., Wilson, K., Hakimi, Z., Lionikaite, V., & Metafuni, E. (2026). Pegcetacoplan Delivers Real‐World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real‐World Clinical and Patient‐Reported Outcomes. European Journal of Haematology. https://doi.org/10.1111/ejh.70228
Vancouver
Llamas JCV, Wilson K, Hakimi Z, Lionikaite V, Metafuni E. Pegcetacoplan Delivers Real‐World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real‐World Clinical and Patient‐Reported Outcomes. European Journal of Haematology. 2026. doi:10.1111/ejh.70228
BibTeX
@article{Llamas2026,
author = {Llamas, Juan Carlos Vallejo and Wilson, Koo and Hakimi, Zalmai and Lionikaite, Vikte and Metafuni, Elisabetta},
title = {Pegcetacoplan Delivers Real‐World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real‐World Clinical and Patient‐Reported Outcomes},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70228}
}
EUVIMED